Eurofins Scient. Stock: Shares Fall Further by 2%, Oddo BHF Lowers Target
The Luxembourg-based bioanalytical testing specialist is among the most penalized stocks in the CAC 40 this Thursday noon. The stock suffers a new weakness as Oddo BHF lowered its price target the day before. The analyst's note weighs on a stock already weakened by poorly received April quarterly results.
Oddo BHF Lowers Target to €67 While Maintaining Neutral Rating
Eurofins Scientific shares are down 2.11% at €61.14, among the steepest declines in the CAC 40, while the Paris index is down 0.48%. The movement comes after Oddo BHF revised its price target from €70 to €67 while maintaining a neutral opinion. The new target implies a theoretical upside of about 9.6% from the current price, but the continued cautious stance reflects the broker's wait-and-see approach to the stock. Sanofi also fell by 1.63% at the same time, with no direct sector link to clarify Eurofins' movement. The downward trend follows a difficult April, after first-quarter accounts were poorly received, already causing a drop of more than 10% at the time of publication.
Eurofins Scientific Below MM50 and MM200, but RSI Remains Neutral
Over three months, Eurofins Scientific has declined by 10.3%, while the annual performance remains positive at 8.17%. The stock is now trading below the MM50 at €62.50 (a gap of -2.18%) and the MM200 at €63.41 (a gap of -3.58%), while slightly above the MM20 at €60.19. This configuration places the stock in a transition zone, with an RSI at 55 indicating a still neutral momentum despite the day's decline. The support threshold identified at €57.54 remains the next technical milestone, a level approached at the beginning of May during the dip to €57.34. However, the resistance at €69.84 appears distant, more than 14% above the current price. In the absence of an upcoming financial calendar, the stock's trajectory will depend on its ability to stabilize above €60.
